Pharma News

The World Health Organization (WHO)  spells out the need to step up cancer services in low and middle-income countries. WHO warns that, if current trends continue, the world will see a 60% increase in cancer cases over the next two decades. The greatest increase (an estimated 81%) in new cases will occur in low- and middle-income countries, where survival rates are currently lowest.

An artificial virus capable of attacking superbug infections resistant to antibiotics has been bioengineered by researchers at UCL, NPL, University of Cambridge, University of Exeter and King’s College London.

Strides Pharma Science Limited (Strides) announced that its step‐down wholly‐owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a definitive asset transfer and licensing agreement with Pharmaceutics International, Inc.(Pii) to acquire 18 ANDAs for the US market.

Cipla Foundation-IISER Pune Centre for Chemistry Education and Research on the IISER Pune campus has been inaugurated by Dr. Yusuf K. Hamied, Non-Executive Chairman, Cipla Ltd. He was accompanied by Mrs. Farida Hamied and Ms. Rumana Hamied, the Managing Trustee of Cipla Foundation. The Centre, housing chemistry research labs along with an in-class demo facility provides space for outreach activities involving teacher and student training and will serve as a platform for developing industry-academia interactions.

U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals 4 years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine. This action was taken because an independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV. Importantly, the DSMB did not express any concern regarding participant safety.

Homicide is a leading cause of death among pregnant and postpartum women in Louisiana, according to an analysis of birth and death records from 2016 and 2017. The study, appearing as a research letter in JAMA Pediatrics, was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The research team was led by Maeve E. Wallace, Ph.D., of Tulane University School of Public Health and Tropical Medicine in New Orleans.

The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products. This joint statement describes key steps the agencies will take to address false or misleading promotion about biosimilars within their respective authorities and deter anti-competitive behavior in this space.

Eminence Business Media’s “3rd Annual Pharma Project & Portfolio Management Summit 2020” concluded on January 23rd & 24th, 2020 at Hotel Hilton, Mumbai. The theme of the summit was “Grooming Project & Portfolio Management teams for opportunities & uncertainties”. The event was an outstanding success with 100+ delegates attending the summit with I2E Consulting, Innoventic Research & Business & ProductDossier Solutions India Pvt. Ltd. partnering the event.

Eminence Business Media organized “Pharma Authors Roundtable” on January 22nd, 2020 at Hotel JW Marriott, Mumbai inviting all the young writers & authors to present their ideas, success stories, case studies on how did they manage/handle a project successfully. This event was Eminence Business Media’s initiative towards creating a platform for established & new authors to get their names featured as the co-author of an upcoming book on project management by Mr. John Robert.